Antibiotherapy - Page 2 de 7

info-atbvac > International News > Antibiotherapy

Aminoglycoside-based regimen as empirical treatment of patients with pyelonephritis : reassuring data. ( Meital Elbaz et al. )

Effectiveness and safety of an institutional aminoglycoside-based regimen as empirical treatment of patients with pyelonephritis.

25 juin | Dr Philippe Lesprit

Aminoglycosides are usually recommended only as second line therapy for the treatment of acute pyelonephritis. However they offer several advantages … Suite

Does short course adjunctive aminoglycoside therapy improve mortality in Gram-negative bloodstream infection? ( J W Timotëus Deelen et al. )

Short course aminoglycosides as adjunctive empiric therapy in patients with Gram negative bloodstream infection, a cohort study.

23 juin | Dr Jean-Pierre Bru

Short-course combination therapy with aminoglycoside in patients with sepsis or septic shock is still a matter of debate. Arguments for … Suite

The quest for optimal treatment durations for uncomplicated cystitis. ( Do Kyung Kim et al. )

Reappraisal of the treatment duration of antibiotic regimens for acute uncomplicated cystitis in adult women: a systematic review and network meta-analysis of 61 randomised clinical trials.

16 juin | Dr Jean-Pierre Bru

International guidelines for the treatment of uncomplicated cystitis recommend 3-day to 7-day regimens, except for fosfomycin trometamol, which is a … Suite

Cefazolin for treating staphylococcal meningitis? ( Paul Le Turnier et al. )

Should we reconsider cefazolin for treating staphylococcal meningitis? A retrospective analysis of cefazolin and cloxacillin CSF levels in patients treated for staphylococcal meningitis.

09 juin | Dr Jean-Pierre Bru

Little is known about the diffusion of cefazolin into CSF. The objective of the study was to assess the meningeal … Suite

Ceftazidime, carbapenems, or piperacillin-tazobactam for Pseudomonas aeruginosa bloodstream infection? ( Tanya Babich et al. )

Ceftazidime, carbapenems, or piperacillin-tazobactam as single definitive therapy for Pseudomonas aeruginosa bloodstream infection - a multi-site retrospective study.

04 juin | Dr Jean-Pierre Bru

The optimal empirical and definitive antibiotic regimens for the treatment of Pseudomonas aeruginosa infections are yet to be defined. One … Suite

Does 1 or 2 g daily of Ceftriaxone affects clinical outcome in ICU patients? ( Andrew Ackerman et al. )

Comparison of Clinical Outcomes among Intensive Care Unit Patients Receiving One or Two Grams of Ceftriaxone Daily.

02 juin | Dr Jean-Pierre Bru

Pharmacokinetic data suggest ICU patients with sepsis, including those with hypoalbuminemia, may experience ceftriaxone underexposure. But clinical outcomes data are … Suite

24 hours stability of Ampicillin and ceftriaxone solution at different temperatures. ( L. Herrera-Hidalgo et al. )

Ampicillin and Ceftriaxone Solution Stability at Different Temperatures Useful for Outpatient Parenteral Antimicrobial Therapy (OPAT).

26 mai | Dr Jean-Pierre Bru

Ampicillin plus Ceftriaxone combined therapy has been widely recommended for the treatment of Enterococcus faecalis infective endocarditis (IE), for a … Suite

Safety and tolerability of prolonged tedizolid treatment. ( Mensa Vendrell M. et al. )

Safety and tolerability of more than 6 days of tedizolid treatment.

19 mai | Dr Jean-Pierre Bru

The second generation oxazolidinone tedizolid is expected to have a better safety profile than that of linezolid, because low MICs … Suite

Risk factors of multidrug resistance of P. aeruginosa in neutropenic patients, identifications and building up a clinical prediction model ( C. Gudiol et al. )

Clinical Predictive Model of Multidrug Resistance in Neutropenic Cancer Patients with Bloodstream Infection Due to Pseudomonas aeruginosa.

15 mai | Dr Olivier Leroy

Pseudomonas aeruginosa (PA) has classically been one of the most important causes of severe sepsis and death among cancer patients … Suite

Unacceptably low sensitivity of procalcitonin for bacteremia. ( Kellie J Goodlet et al. )

Low Sensitivity of Procalcitonin for Bacteremia at an Academic Medical Center: A Cautionary Tale for Antimicrobial Stewardship.

12 mai | Dr Jean-Pierre Bru

Although procalcitonin (PCT) has been proposed for stewardship programs (including in ICU) to reduce the initiation and continuation of unnecessary … Suite